Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
NCT04060862 · Hoffmann-La Roche · PHASE1 · terminated · last registry update 2024-11-08 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The decision to not open the Phase III portion was based on a strategic sponsor decision and not driven by any safety concerns.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-27Results posted on the registry: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2025-05-28Results posted on the registry: Rutgers, The State University of New Jersey, a drug against AKT2 (NCT03326713)
- 2025-05-21Phase 3 first posted: Relay Therapeutics, Inc., Zovegalisib + Capivasertib (NCT06982521)
- 2025-01-08Phase 3 first posted: AstraZeneca, Fulvestrant + Capivasertib (NCT06764186)
- 2024-10-30Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Paclitaxel (NCT03800836)
- 2024-10-10Phase 3 first posted: AstraZeneca, Capivasertib + Fulvestrant (NCT06635447)
- 2024-06-04Also stopped (terminated): Merck Sharp & Dohme LLC, MK-2206 + Trastuzumab (NCT00963547)
- 2024-03-27Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Ipatasertib (NCT04177108)
- 2024-03-12Results posted on the registry: Hoffmann-La Roche, Ipatasertib + Paclitaxel (NCT03337724)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision